MICHAEL B COHEN, MD
Medical Practice at Hawkins Dr, Iowa City, IA
License number
Iowa 27765
Category
Medical Practice
Type
Cytopathology
Address
Address
200 Hawkins Dr, Iowa City, IA 52242
Phone
(319) 384-9609
(319) 384-9613 (Fax)
(319) 384-9613 (Fax)
Professional information
Dr. Michael B Cohen, Salt Lake City UT - MD (Doctor of Medicine)
Specialties:
Cytopathology
Address:
1950 Circle Of Hope Dr STE N3100, Salt Lake City 84112
UI Hospitals and Clinics
200 Hawkins Dr, Iowa City 52242
(319) 384-8442 (Phone), (319) 384-7345 (Fax)
UNIVERSITY OF IOWA HOSPITALS AND CLINICS
200 Hawkins Dr, Iowa City 52242
(319) 356-1616 (Phone), (319) 356-7533 (Fax)
HUNTSMAN CANCER INSTITUTE
1950 Circle Of Hope Dr, Salt Lake City 84112
(801) 585-0236 (Phone)
UI Hospitals and Clinics
200 Hawkins Dr, Iowa City 52242
(319) 384-8442 (Phone), (319) 384-7345 (Fax)
UNIVERSITY OF IOWA HOSPITALS AND CLINICS
200 Hawkins Dr, Iowa City 52242
(319) 356-1616 (Phone), (319) 356-7533 (Fax)
HUNTSMAN CANCER INSTITUTE
1950 Circle Of Hope Dr, Salt Lake City 84112
(801) 585-0236 (Phone)
Certifications:
Anatomic Pathology, 1987, Cytopathology, 1996, Pathology Recertification, 1998
Awards:
Healthgrades Honor Roll
Languages:
English, Dutch
Hospitals:
1950 Circle Of Hope Dr STE N3100, Salt Lake City 84112
UI Hospitals and Clinics
200 Hawkins Dr, Iowa City 52242
UNIVERSITY OF IOWA HOSPITALS AND CLINICS
200 Hawkins Dr, Iowa City 52242
HUNTSMAN CANCER INSTITUTE
1950 Circle Of Hope Dr, Salt Lake City 84112
University of Iowa Hospital and Clinics
200 Hawkins Dr, Iowa City 52242
UI Hospitals and Clinics
200 Hawkins Dr, Iowa City 52242
UNIVERSITY OF IOWA HOSPITALS AND CLINICS
200 Hawkins Dr, Iowa City 52242
HUNTSMAN CANCER INSTITUTE
1950 Circle Of Hope Dr, Salt Lake City 84112
University of Iowa Hospital and Clinics
200 Hawkins Dr, Iowa City 52242
Education:
Medical School
Albany Medical College
Graduated: 1982
Albany Memorial Hospital
U Calif Hosps-Clins
U Calif Hosps-Clinics
Albany Medical College
Graduated: 1982
Albany Memorial Hospital
U Calif Hosps-Clins
U Calif Hosps-Clinics
Michael Benjamin Cohen, Iowa City IA
Specialties:
Pathology, Cytopathology, Anatomic Pathology, Pathology Recertification
Work:
University of Iowa
200 Hawkins Dr, Iowa City, IA 52243
200 Hawkins Dr, Iowa City, IA 52243
Education:
Albany Medical College (1982)
Prostate Cell Surface Antigen-Specific Antibodies
US Patent:
6512096, Jan 28, 2003
Filed:
Jan 9, 2001
Appl. No.:
09/757336
Inventors:
George J. Weiner - Iowa City IA
Oskar W. Rokhlin - Coralville IA
Michael B. Cohen - Iowa City IA
Oskar W. Rokhlin - Coralville IA
Michael B. Cohen - Iowa City IA
Assignee:
University of Iowa Research Foundation - Iowa City IA
International Classification:
A61K 34395
US Classification:
53038885, 5303873, 5303881, 5303917
Abstract:
Disclosed is an antibody that binds to a protein found on normal and cancerous prostate cells, but not found on nonprostate cells and a hybridoma that produces the antibody to the prostate-specific protein. Also disclosed are antibodies conjugated to labels or cytotoxic moieties.
Evaluation Of Adenocarcinoma Of The Prostate And Breast Using Anti-Dystroglycan Antibodies
US Patent:
6379893, Apr 30, 2002
Filed:
Jun 15, 2000
Appl. No.:
09/594433
Inventors:
Kevin P. Campbell - Iowa City IA
Michael Henry - Maynard MA
Michael B. Cohen - Iowa City IA
Michael Henry - Maynard MA
Michael B. Cohen - Iowa City IA
Assignee:
University of Iowa Research Foundation - Iowa City IA
International Classification:
C12O 168
US Classification:
435 6, 4352402, 4352523, 4353201, 530350, 536 235
Abstract:
Disclosed is a method for diagnosing the tumorigenic grade of a malignant tissue. The method entails determining the amount of dystroglycan protein of the malignant tissue relative to a standard. Suitable methods for determining the amount of dystroglycan protein of the tissue are provided, and include measuring the amount of mRNA transcripts which encode dystroglycan, and also performing western blot analysis or immunofluorescence analysis on the tissue components to detect -dystroglycan or -dystroglycan. An antibody probe which binds specifically to the C-terminus of -dystroglycan, is provided. This method is applicable to human malignant tissue, especially adenocarcinoma, and preferably prostate or mammary adenocarcinoma. This method can also be applied to the detection of a cancerous disease state in a tissue of a patient, with a decreased level of dystroglycan protein being indicative of the presence of cancer. Also disclosed is a method for determining the prognosis of a patient afflicted with a malignancy by determining the expression level of the dystroglycan gene in a tissue sample of the malignancy, and comparing the expression level to a standard, with a decreased level of dystroglycan expression being indicative of unfavorable prognosis.
Prostate Cell Surface Antigen-Specific Antibodies
US Patent:
6207805, Mar 27, 2001
Filed:
Jun 25, 1998
Appl. No.:
9/104717
Inventors:
George J. Weiner - Iowa City IA
Oskar W. Rokhlin - Coralville IA
Michael B. Cohen - Iowa City IA
Oskar W. Rokhlin - Coralville IA
Michael B. Cohen - Iowa City IA
Assignee:
University of Iowa Research Foundation - Iowa City IA
International Classification:
A61K34/395
US Classification:
53038885
Abstract:
Disclosed is an antibody that binds to a protein found on normal and cancerous prostate cells, but not found on nonprostate cells and a hybridoma that produces the antibody to the prostate-specific protein. Also disclosed are antibodies conjugated to labels or cytotoxic moieties.